The First Combination in Cancer Treatment: The CMF (Cyclophosphamide + Methotrexate + 5-FU) Regimen
In this article
What Is the CMF Regimen?
CMFis a combination of three chemotherapy drugs: Cyclophosphamide, Methotrexate and 5-Fluorouracil (5-FU). First used for breast cancer in the late 1960s / early 1970s, it is considered a milestone in modern solid tumor oncology.
For the first time, CMF showed that breast cancer was not confined to the breast: microscopic disease might already have spread elsewhere at diagnosis, and these invisible cells could be targeted with systemic chemotherapy . This approach laid the foundation for what we now call “adjuvant chemotherapy,” treatment after surgery to prevent recurrence.
Why Was It a Historical Turning Point?
- Before CMF, breast cancer was largely viewed as a surgical disease: the tumor was removed and the patient considered “clear.” Yet years later, disease could return in bone, lung, or liver.
- CMF established for the first time that breast cancer could be a systemic disease from the outset; micrometastases might already be circulating at diagnosis.
- This led to the idea of giving chemotherapy even after tumor removal (after mastectomy) to reduce recurrence risk . This strategy, “adjuvant chemotherapy,” remains standard today.
- CMF became one of the first multidrug breast cancer regimens shown to prolong survival, changing the disease's prognosis.
CMF Components and Mechanisms
| Drug | Class | Simplified Mechanism of Action |
|---|---|---|
| Cyclophosphamide | Alkylating agent (DNA-damaging) | Forms crosslinks in cancer cell DNA, preventing division. Rapidly proliferating cells cannot repair this damage and die. |
| Methotrexate | Antimetabolite (folate antagonist) | Blocks the folate cycle, preventing cancer cells from accessing the building blocks needed for DNA synthesis. The cell cannot find “fuel to operate.” |
| 5-Fluorouracil (5-FU) | Antimetabolite (pyrimidine analogue) | Acts as a false building block in DNA and RNA synthesis, disrupting proliferation. This particularly suppresses rapidly dividing tumor cells. |
Which Patients Received CMF?
- Early-stage breast cancer: As adjuvant treatment after surgical tumor removal (mastectomy or breast-conserving surgery) to eliminate micrometastatic disease and reduce recurrence risk.
- Lymph node-positive patients: Systemic recurrence risk is particularly high with axillary lymph node involvement. CMF provided significant benefit in this group, supporting aggressive treatment for node-positive breast cancer.
- More advanced disease (metastatic breast cancer): Used palliatively to reduce tumor burden and control symptoms.
Today: CMF is no longer the first choice for most patients because more effective anthracycline- (doxorubicin) and taxane-containing (paclitaxel, docetaxel) regimens have emerged. It remains an option for selected patients with limited cardiac function, certain comorbidities, or intolerance to anthracyclines/taxanes.
How Was CMF Administered?
Historical CMF schedules used cycles lasting several weeks. Cyclophosphamide was usually oral or intravenous; methotrexate and 5-FU were intravenous on specified days. Cycles repeated every 4 weeks, with several cycles planned in total (e.g., 6 cycles).
Any current use is modified for the patient and center (oral–IV combinations, administration on days 1-8, etc.). CMF is therefore not a single fixed prescription but a schedule with slight variations between centers while retaining the same core structure.
| Component | Conventional Route | Administration Schedule |
|---|---|---|
| Cyclophosphamide | Oral or intravenous | Usually daily or on specified days in each cycle |
| Methotrexate | Intravenous (IV push / short infusion) | Usually on specified cycle days (e.g., day 1 and day 8) |
| 5-Fluorouracil | Intravenous (IV) | Given on the same days as methotrexate |
CMF Side Effects
Common / Expected Effects
- Nausea, vomiting (particularly related to cyclophosphamide and 5-FU)
- Mouth sores (mucositis) – methotrexate and 5-FU can irritate the oral mucosa
- Hair loss (alopecia), sometimes complete and sometimes partial
- Fatigue and weakness
- Immunosuppression: Low leukocyte count → increased infection risk
More Serious but Less Common Effects
- Severe neutropenia: Can profoundly suppress immunity and lead to febrile neutropenia, an emergency that may require hospitalization.
- Hematologic toxicity: Low platelets (easy bruising, bleeding) and reduced hemoglobin (tiring easily, shortness of breath).
- Organ toxicity: High cumulative cyclophosphamide doses may cause bladder toxicity (hemorrhagic cystitis); high-dose methotrexate can strain the liver; 5-FU may cause rare but important cardiac side effects (chest pain, spasm-like events).
Who Receives CMF Today?
CMF is no longer a “default first choice” in current oncology practice. More powerful and better-tolerated protocols are available (such as anthracycline + taxane combinations or trastuzumab-containing regimens in HER2+ disease).
Nevertheless, CMF may still be considered for:
- Patients for whom anthracyclines (e.g., doxorubicin) are unsuitable because of cardiac risk
- Patients unable to tolerate taxanes (paclitaxel, docetaxel)
- Selected postmenopausal or frail patients who need less intensive but still systemic chemotherapy
SGK Reimbursement and Practice in Türkiye
CMF is a combination protocol of generic chemotherapy drugs, not a single commercial product. These drugs (cyclophosphamide, methotrexate, 5-FU) have long been available in Türkiye as standard chemotherapy agents reimbursed by SGK.
How Is Follow-Up and Monitoring Performed?
- Blood counts: White blood cells, neutrophils, platelets, and hemoglobin are measured before each cycle.
- Kidney and liver function tests: Particularly important for methotrexate clearance and 5-FU toxicity.
- Clinical examination: Assess mouth sores, hand–foot syndrome-like skin findings, weight loss, and signs of infection.
- Imaging: Depending on disease stage, tumor response may be monitored at intervals with CT, MRI, or PET-CT. In early-stage adjuvant treatment, the main aim is recurrence prevention, so clinical follow-up and imaging when needed are used.
References
- Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976.
- DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008.
- Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. 6th ed.
- Fisher B et al. “Adjuvant chemotherapy in node-positive breast cancer”: landmark studies showing the survival impact of early systemic treatment.
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: meta-analyses of randomized trials.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.